Fortrea Holdings is trading 4.6% higher at $24.72 after hours, with no confirmed late-breaking catalyst in available coverage.
- The move compares with its October 23 regular-session close of $23.63.
- On October 23, Fortrea announced an Omico collaboration to advance biomarker-led oncology drug development; the announcement does not establish a direct connection to the rise.
- Broader market conditions were mixed-to-negative and do not clearly explain the gain.